Barinthus Biotherapeutics plc Stock Price, News & Analysis

Barinthus Bio (NASDAQ: BRNS) reported Q3 2025 results and corporate updates, including a definitive all-stock merger agreement with Clywedog and clinical updates for VTP-1000.

Key facts: cash of $75.7M as of Sept 30, 2025 (down $12.1M QoQ); R&D expense $5.4M in Q3 vs $8.0M in Q2; impairment of long-lived assets $4.7M in Q3; net loss $14.6M, $(0.36) per share. Single ascending dose data for VTP-1000 expected before end of 2025; MAD data expected H2 2026. Transaction expected to close H1 2026 and the combined company will trade as CLYD with cash runway into 2027.

Clywedog Therapeutics (formerly Barinthus Therapeutics; NASDAQ: BRNS) and Barinthus have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. ChemDiv will continue providing chemistry, computational, and clinical pharmacology support as the combined company advances clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D) and celiac disease. The merged company is expected to list on Nasdaq under the ticker CLYD upon closing, with transaction closing targeted for the first half of 2026. The portfolio includes three clinical-stage assets and multiple near-term data milestones; ChemDiv says its services helped progress discovery programs to clinic in less than three years.

Barinthus Biotherapeutics (NASDAQ: BRNS) announced a strategic merger with private company Clywedog Therapeutics in an all-stock transaction. The combined entity will focus on developing treatments for metabolic and autoimmune diseases, featuring three clinical-stage candidates targeting Type 1 Diabetes, Type 2 Diabetes, and Celiac Disease.

The merger will result in Clywedog shareholders owning 66% of the combined company, with Barinthus shareholders holding the remaining 34%. The combined company, to be renamed Clywedog Therapeutics, will trade on NASDAQ as "CLYD" and expects four key clinical milestones within 18 months post-closing. The transaction, backed by OrbiMed and Torrey Pines, is expected to close in H1 2026, with a cash runway extending through 2027.

Barinthus Bio (NASDAQ: BRNS) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $87.8 million in cash, projecting runway into 2027. Key developments include the initiation of the final cohort in the Phase 1 AVALON trial's Single Ascending Dose (SAD) portion for VTP-1000 in celiac disease, with data expected in early Q4 2025.

Q2 financial highlights show R&D expenses of $8.0 million (down from $8.3M in Q1) and G&A expenses of $15.4 million (up from $12.6M in Q1). The company reported a net loss of $21.1 million ($0.52 per share). The VTP-850 prostate cancer trial completed with encouraging immunogenicity data, and the company is actively seeking partners for multiple programs.

Barinthus Biotherapeutics (BRNS) announced that CEO Bill Enright will be presenting at the upcoming Investor Summit Virtual event on June 10, 2025. The presentation will take place virtually, offering investors an opportunity to learn more about the company's developments and strategy. The event provides a platform for Barinthus to engage with the investment community and share their corporate vision.

Barinthus Bio (NASDAQ: BRNS) reported Q1 2025 financial results and corporate updates. The company's lead asset VTP-1000, targeting celiac disease, is progressing with Phase 1 single ascending dose data expected in Q3 2025. The company presented encouraging results from two Phase 2 trials (HBV003 and IM-PROVE II) for chronic hepatitis B treatment at EASL 2025. Key financial highlights include cash position of $100.6 million as of March 31, 2025, providing runway into 2027. Q1 2025 showed reduced R&D expenses at $8.3 million (vs $11.1 million in Q1 2024) and increased G&A expenses at $12.6 million (vs $6.0 million in Q1 2024). The company reported a net loss of $19.6 million ($0.49 per share) compared to $15.5 million ($0.40 per share) in Q1 2024. Barinthus is strategically refocusing on immunology and inflammation indications while seeking partners for its viral vector platforms.

Barinthus Bio (NASDAQ: BRNS) has reported its full year 2024 financial results and corporate updates, highlighting its strategic transformation into an immunology and inflammatory disease-focused company. The company's lead asset, VTP-1000, a potentially curative immunotherapy for celiac disease, is progressing with first data expected in Q3 2025.

Key financial highlights include:

• Cash position of $112.4 million as of December 31, 2024
• Revenue of $15.0 million in 2024, up from $0.8 million in 2023
• Net loss of $61.1 million ($1.55 per share)
• Research and development expenses of $42.2 million

The company's SNAP-TI platform shows promise in promoting antigen-specific immune tolerance. In chronic hepatitis B trials, VTP-300 demonstrated encouraging results with eight participants achieving undetectable HBsAg levels. The company's cash runway is expected to extend into 2027.

Barinthus Biotherapeutics has announced its participation in the upcoming Investor Summit Virtual event scheduled for March 11, 2025. The company will be represented by CEO Bill Enright and CFO Gemma Brown at this significant investor conference.

Barinthus Bio announced a strategic shift to focus on Immunology and Inflammation (I&I) with a priority on developing VTP-1000 for celiac disease, expecting Phase 1 data by mid-2025. The company will halt further development of VTP-300 for chronic hepatitis B (CHB) until a partner is found. To extend its cash runway to early 2027, Barinthus will cut costs by reducing its workforce by 65% and closing its U.K. site, focusing future operations in Germantown, Maryland.

Financially, the company reported $112 million in cash and equivalents as of December 31, 2024. This restructuring aims to streamline operations and align resources with its new strategic focus. Key 2025 milestones include:

• Mid-2025: Phase 1 data for VTP-1000 in celiac disease.
• Q3 2025: Start of multiple ascending dose Phase 1 trial for VTP-1000.
• Q2 2025: Results from Phase 2b HBV003 and Phase 2a IM-PROVE II trials for VTP-300 in CHB.
• Q2 2025: Results from Phase 1 PCA001 trial for VTP-850 in prostate cancer.

CEO Bill Enright emphasized the company's commitment to leveraging its SNAP-TI platform for autoimmune diseases and expressed gratitude to departing executives and staff.